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In thisMinireview, we discuss basic aspects of germinal center biology in the context of immunity to
influenza infection and speculate on how the simultaneous evolutionary races of virus and antibody
may impact our efforts to design a universal influenza vaccine.Introduction
Influenza epidemics cause millions of infections and hundreds of
thousands of deaths worldwide each year and cost nearly $100
billion per year in the United States alone. The influenza vaccine
is generally protective against the strains from which it is
composed. However, effectiveness wanes as herd immunity
pushes the viral envelope proteins to mutate and evolve (anti-
genic drift). Periodically, more antigenically distinct or virulent
influenza strains arise due to recombination among zoonotic
strains (antigenic shift). These strains can cause pandemics
such as the 1918 Spanish flu, which had a death toll of tens of
millions of people.
Theprimary target of anti-influenza antibodies is the hemagglu-
tinin (HA) protein, a trimer consisting of a membrane (envelope)-
embedded stalk region and an expanded globular head onwhich
the receptor-binding site (RBS) is located. Most protective anti-
bodies against HA bind to regions surrounding the RBS that are
highly mutable, which allows antigenic drift and immune escape.
However, rare antibodies have been isolated that bind function-
ally critical regions of HA that are much less susceptible to anti-
genic drift (Krammer and Palese, 2015; Schmidt et al., 2015).
These antibodies bind either within the RBS, mimicking the sialic
acid ligands of HA, or to regions of the HA stalk that are critical for
viral fusion to host cell membranes (Figure 1A). A major goal of
vaccinologists is to develop a universal vaccine capable of elicit-
ing protective antibodies to epitopes that are common among
influenza strains and that are stable over time, thus circumventing
antigenic variation (Krammer and Palese, 2015).
Antibodies attain high affinity through somatic hypermutation
(SHM) of immunoglobulin (Ig) genes in B cells following exposure
to antigen in a process known as affinity maturation (Eisen,
2014). Most antibodies to influenza cloned from humans are
heavily mutated, and these mutations are likely critical for
broadly protective binding to the virus (Lingwood et al., 2012;
Pappas et al., 2014; Schmidt et al., 2015). Affinity maturation
takes place in germinal centers (GCs) (Victora and Nussenzweig,
2012), where B cells undergo SHM and are subsequently
selected based on the ability of their mutant Igs to bind antigen.
A fundamental constraint to this process is that GCs select for
antibodies with higher affinity for antigen (or some close corre-late of it) but are ‘‘agnostic’’ when it comes to their protective ef-
ficacy—including their ability to neutralize virus or kill infected
cells and their potential to cross-react with other strains of the of-
fending pathogen (breadth). For many infectious diseases, this
‘‘evolution by proxy’’ is sufficient to provide robust immunity.
However, in cases like influenza, antigenic drift renders high-af-
finity protective antibodies from one season ineffective against
newly emerging strains.
GC Kinetics and Structure
Antigenic stimulation triggers specific B and T cells to move to-
ward the T zone/follicle (T:B) border area of secondary lymphoid
organs. There, B cells that present antigen-derived peptides to
helper T cells become ‘‘authorized’’ to engage in a productive
immune response. Successful B cells enter one of three devel-
opmental paths: they can differentiate into plasma cells (PCs)
that secrete early, low-affinity antibody; they can re-establish a
nonproliferative state and join the memory B cell pool; or they
can enter the GC reaction (Figure 1B) (Victora and Nussenzweig,
2012).
GCs appear several days after antigen exposure as clusters of
rapidly proliferating cells in the center of B cell follicles. GCs
comprise two anatomically defined areas: the dark zone (DZ),
where cells proliferate and hypermutate their Ig genes, and the
light zone (LZ), where antigen-driven selection takes place (Vic-
tora and Nussenzweig, 2012). Following DZ hypermutation, B
cells migrate to the LZ, where antigen is deposited as immune
complexes on the surface of follicular dendritic cells (FDCs). LZ
B cells compete to bind and retrieve antigen from FDCs and pre-
sent it to GC-resident T follicular helper (Tfh) cells. B cells that
have acquired higher affinity by virtue of SHM are more likely
to receive positive selection signals, triggering their return to
the DZ for further proliferation and hypermutation (cyclic re-en-
try, Figure 1B). GC selection is thus reminiscent of Darwinian
evolution: iterative cycles of descent withmodification (SHM) fol-
lowed by fitness (affinity)-based selection lead to increased
fitness of the population as a whole. Sporadic differentiation of
positively selected LZ B cells into PCs and memory B cells re-
sults in the progressive increase in the affinity of serum anti-
bodies over time and upon re-immunization (Figure 1B).Cell 163, October 22, 2015 ª2015 Elsevier Inc. 545
Figure 1. The Germinal Center Response to
Influenza
(A) Residue conservation among seasonal H1 HA
isolates (1975–2005). Conservation is shown for
one monomer on a scale from blue (most
conserved) to white (most variable). Red residues
indicate common glycosylation sites. The RBS is
marked with a star. Image courtesy of Stephen C.
Harrison.
(B) Overview of affinity maturation in the GC.
Cyclic migration of B cells between light and dark
zones drives affinity maturation. Prior to GC entry
and upon positive selection, B cells can differen-
tiate into the PC or memory fates.
(C) Proposed model for re-establishment of im-
munodominance to strain-specific epitopes. Top:
exposure to Strain 1 of influenza generates a
response mostly focused on immunodominant,
Strain-1-specific epitopes (red) but also induces
a subdominant cross-reactive response (green).
Middle: exposure to a divergent Strain 2 will
initially reactivate cross-reactive memory cells
(green) from the response to Strain 1, generating
a ‘‘broad’’ response, but will also prime
Strain-2-specific clones de novo, which will
eventually outcompete the cross-reactive clones.
Bottom: re-exposure to Strain 2 will preferentially
recall Strain-2-specific clones, reinstating im-
munodominance.The cues that trigger B cells to choose between cyclic re-entry
and differentiation into PCs ormemory B cells are unknown. High
affinity for antigen appears to be a pre-requisite for PC differen-
tiation and/or survival (Goodnow et al., 2010). However, because
PC differentiation occurs after clonal expansion, diversion of part
of a clone into the PC fate does not preclude further diversifica-546 Cell 163, October 22, 2015 ª2015 Elsevier Inc.tion of the same expanded clone in GCs.
Also under scrutiny is the relative propen-
sity of memory B cells to re-enter GCs for
further diversification, rather than exclu-
sively differentiating into secondary PC
(McHeyzer-Williams et al., 2015). The
ability to sequentially diversify the same
clone over multiple responses is likely to
be crucial to eliciting a broad response
to influenza.
Selection of High-Affinity Mutants
in the GC
Twomodels for how affinity-based selec-
tion operates in GCs are traditionally pro-
posed. The first, and simplest, centers on
antigen-driven signaling through the B
cell receptor (BCR, comprising surface
Ig, Iga, and Igb) as the direct driver of
selection. In this model, Ig with highest
affinity for antigen will bind more strongly
to immune complexes deposited on LZ
FDCs, which triggers their return to the
DZ and further proliferation (Victora and
Nussenzweig, 2012). A recent develop-
ment is the debate over whether BCRsignaling is even active in GC B cells undergoing selection in
the LZ and the role that inhibition of BCR signaling by Fc recep-
tors might play in this process (Espe´li et al., 2012; Khalil et al.,
2012).
The second model of selection proposes that, rather than
competing for direct signals from antigen, GC B cells compete
for limiting amounts of Tfh cell help. Here, the primary role of
the BCR in selection is to trigger endocytosis: B cells acquire
and present antigen in proportion to the affinity of their Ig. This
maps Ig affinity—a B cell intrinsic property—onto surface pep-
tide-MHC (pMHC) density—a feature that can be distinguished
by Tfh cells. Several aspects of this model have been validated
experimentally, and forcing interaction of GC B cells with Tfh is
the only experimental approach so far that has been successful
in triggering positive selection of GC B cells in vivo (Victora and
Nussenzweig, 2012).
These two models are closely interrelated and thus not mutu-
ally exclusive. For example, strong inhibition by Fc receptors
could serve to blunt BCR signaling so that B cells rely more
heavily on T cells for selection. On the other hand, signals from
T cells could potentially relieve Fc-mediated repression, allowing
for productive BCR signals only in selected cells.
Establishing themechanism of GC-positive selection can have
important consequences to our understanding of how broadly
protective antibodies develop. A recent report by Wang et al.
(2015) has shown that levels of antibodies with sialylated Fcs in
trivalent influenza vaccine (TIV) recipients 7 days after vaccination
predicted theaffinityof theanti-HA response2weeks later. Vacci-
nation of mice with sialylated (versus non-sialylated) HA immune
complexes generated antibodies capable of heterosubtypic
protection in an in vivo challenge model. The authors traced this
effect back to the upregulation of inhibitory Fc receptor FcgRIIB
in GC B cells by sialylated Fcs, which would increase the
threshold for BCR-driven selection, altering the affinity and/or
specificity of theensuing response.On theotherhand,Tcell prim-
ing with plasmid DNA encoding H1 prior to immunization with
seasonal vaccine also increased the frequency of cross-reactive
antibodies directed to the HA stem (Wei et al., 2010). While the
mechanistic basis for this subversion of immunodominance is
not clear, a likely scenario is that increased CD4 T cell priming
may have led to relaxed interclonal competition between B cells
before and within GCs because T cell help became less limiting.
Clonal Diversity and Immunodominance in the Antibody
Response
The naive B cell repertoire comprises a large number of distinct
V(D)J rearrangements, each expressed by only one or a few cells
that proliferate to form clones upon antigenic exposure. B cells
with low or even undetectable affinity for HA are capable of being
recruited into GCs (Lingwood et al., 2012).
Competition between B cell clones (interclonal competition)
somewhat limits the access of lower-affinity B cells to the early
GC. This clonality is further restricted in mature GCs by com-
bined competition between clones and among SHM variants of
the same clone (intraclonal competition) (Eisen, 2014; Victora
and Nussenzweig, 2012). Competition is thought to lead to pro-
gressive loss of clonal diversity in the responding population.
Thus, only a fraction of B cells remains in the immune response
long enough to acquire the somatic mutations required to confer
high affinity, leading to immunodominance. The immune system
must therefore tune competition to the right level to balance af-
finity and diversity—if too stringent, average population affinity
will increase fast but at the expense of diversity, and if too lax,
diversity will remain high, but affinity will increase only slowly.Immunodominance appears to be a key factor in preventing
the emergence of broadly neutralizing influenza antibodies. Anti-
bodies against epitopes that are conserved between different
HA variants, such as the HA stem or the RBS, are underrepre-
sented when compared to antibodies to more variable regions
on the HA globular head. Potential reasons for this are that anti-
bodies that bind these conserved epitopes require particular
amino acid sequence elements (Lee and Wilson, 2015; Schmidt
et al., 2015) and that conserved regions represent a relatively
small or inaccessible portion of the HA surface (Figure 1A).
Conversely, epitopes in the more variable regions of HA that
are permissive to antigenic drift aremore abundant, more acces-
sible on the intact virion, and can be targeted in a multitude of
ways. Evolutionary pressure on the virus may have led to the
development of these variable but immunodominant epitopes
as decoys, thus protecting conserved sites.
When exposed to a novel influenza strain for the first time,
conserved epitopes are the only ones to which memory B cells
exist. Thus, novel influenza strains can activate memory B cells
that are cross-reactive to conserved epitopes, even predomi-
nantly generating a broad response (Wrammert et al., 2011;
Ellebedy et al., 2014). However, re-exposure to a novel strain
will shift the response predominantly toward antibodies on the
globular head, reinstating its immunodominance (Ellebedy
et al., 2014). We propose that such immunodominance is due
in large part to GC (and potentially pre-GC) selection steering
the antibody response away from conserved but subdominant
epitopes toward more immunodominant ones (Figure 1C). Two
factors that could contribute to re-establishing immunodomi-
nance are a greater potential of epitopes on the variable portion
of HA to drive affinity maturation and incomplete conservation of
cross-reactive epitopes between variant influenza strains. Thus,
cross-reactive memory B cells may have sufficient affinity to
become PCs and re-enter GCs upon exposure to a novel strain
but could nonetheless be outcompeted in the course of the
response by primary B cell clones undergoing de novo affinity
maturation toward drifted but more immunodominant epitopes
(Figure 1C).
The importance of GC selection for immunodominance is illus-
trated by a recent experiment in mice. Repeated administration
of a low dose of the immune-suppressant rapamycin during
influenza immunization abolished the GC response, which sur-
prisingly was followed by increased resistance to heterosubtypic
challenge and a change in the HA epitopes targeted by the
resulting antibodies (Keating et al., 2013). The mechanistic rea-
sons for this shift are unclear but are likely related to relaxed
competition in the absence of a GC response. This observation
suggests that immunodominance of certain regions of HA
over others is not set in stone and can potentially be over-
come by optimizing vaccination strategies to skew interclonal
competition.
Approaches for Vaccination
Universal vaccination to influenza would require an antibody
response that not only neutralizes all existent strains but also
from which no variant can escape by mutation. Epidemiological
evidence suggests that responses of such type can be elicited.
For example, the broadly protective responses of humans toCell 163, October 22, 2015 ª2015 Elsevier Inc. 547
the 2009 pandemic H1N1 strain may have caused the eradica-
tion of the previous H1N1 lineage that had infected humans for
91 years since the 1918 pandemic but no longer circulates
(Krammer and Palese, 2015). Epidemiological studies aimed at
identifying individuals who are completely immune to one or
more influenza subtypes may help determine the required fea-
tures of a universally protective immune response in a manner
similar to what has been achieved in recent years by studying
HIV-infected individuals (Klein et al., 2013).
A recent study by Schmidt et al. (2015) provides a glimpse of
what a universally protective response might look like. In one in-
dividual, a series of clonally unrelated antibodies were found that
bind to the conserved RBS pocket from different angles. In this
case, mutations in the rim of the pocket, which normally render
RBS antibodies ineffective against antigenic drift, are effective
in preventing neutralization by only one or a few of these anti-
bodies, but never all of them. Thus, perhaps a ‘‘team’’ of neutral-
izing antibodies may be able perform a function that would be
impossible for any single bNAb.
Several studies in the literature have suggested strategies
to elicit broadly neutralizing responses (Krammer and Palese,
2015). These follow along two broad lines: the first aims at devel-
oping immunization with a variety of natural or engineered
antigens designed to force the immune system to focus on
cross-reactive epitopes. These approaches include simulta-
neous or sequential immunization with different natural HA pro-
teins, truncated (e.g., stem only) or chimeric (e.g., conserved
stem, ‘‘exotic’’ head) HA variants, and/or viruses of varied sub-
type. The rationale is to attempt to overcome immunodominance
by either eliminating strain-specific immunodominant epitopes
or providing a competitive advantage to B cell clones that recog-
nize epitopes common to multiple divergent HAs. Two recent
reports highlight the promise of such strategies for inducing
cross-reactive antibodies inmultiple animal models (Impagliazzo
et al., 2015; Yassine et al., 2015).
The second set of approaches relies on using standard anti-
gens while manipulating the rules of selection in the antibody
response. Some of these were discussed above (immunization
with immune complexes, rapamycin treatment, and DNA prim-
ing). Strategies based on increasing Tfh help have been particu-
larly of interest, given the great emphasis on Tfh cells as the
‘‘judges’’ of GC selection (Victora and Nussenzweig, 2012). A
question that remains unsolved is what effect changing Tfh
numbers has on selection: while fewer Tfh cells may promote
stronger competition and therefore maximize the rate of affinity
maturation, more Tfh may be desirable to maximize the size,
quantity, and duration of GCs and perhaps allow for the appear-
ance and maintenance of subdominant B cell clones. Evidence
that adjuvants such asMF59 can expand the breadth of epitopes
targeted by humans to include more of the conserved epitopes
provides proof-of-principle evidence that manipulating the
immune response can lead to increased clonal diversity (Del Giu-
dice and Rappuoli, 2015).
Once a broadly protective response can be achieved by vacci-
nation, a final issue that will need to be addressed is the longevity
of the broadly protective response. That is, can an established
broadly protective response resist challenge by immunodomi-548 Cell 163, October 22, 2015 ª2015 Elsevier Inc.nant responses to drifting or non-protective epitopes eventually?
Further understanding of the basic biology of recall responses
and maintenance of long-lived PC will be required to address
these issues.
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